117 related articles for article (PubMed ID: 9408400)
1. Efficacy of prevention of thromboembolic complications with LMW-heparin in experiment.
Szücs G; Mikó I; Ajzner E; Póti L; Szepesi K; Furka I
Acta Chir Hung; 1997; 36(1-4):356-8. PubMed ID: 9408400
[TBL] [Abstract][Full Text] [Related]
2. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
[TBL] [Abstract][Full Text] [Related]
3. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
Mismetti P; Laporte-Simitsidis S; Navarro C; Sié P; d'Azemar P; Necciari J; Duret JP; Gaud C; Decousus H; Boneu B
Thromb Haemost; 1998 Jun; 79(6):1162-5. PubMed ID: 9657442
[TBL] [Abstract][Full Text] [Related]
4. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.
Boneu B; Navarro C; Cambus JP; Caplain H; d'Azemar P; Necciari J; Duret JP; Gaud C; Sié P
Thromb Haemost; 1998 Feb; 79(2):338-41. PubMed ID: 9493587
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
[TBL] [Abstract][Full Text] [Related]
7. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis.
Lopaciuk S; Bielska-Falda H; Noszczyk W; Bielawiec M; Witkiewicz W; Filipecki S; Michalak J; Ciesielski L; Mackiewicz Z; Czestochowska E; Zawilska K; Cencora A
Thromb Haemost; 1999 Jan; 81(1):26-31. PubMed ID: 9974369
[TBL] [Abstract][Full Text] [Related]
8. Thromboembolic prophylaxis in orthopaedic trauma patients: a comparison between a fixed dose and an individually adjusted dose of a low molecular weight heparin (nadroparin calcium).
Haentjens P
Injury; 1996 Jul; 27(6):385-90. PubMed ID: 8881132
[TBL] [Abstract][Full Text] [Related]
9. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
Turpie AG; Bauer KA; Davidson BL; Fisher WD; Gent M; Huo MH; Sinha U; Gretler DD;
Thromb Haemost; 2009 Jan; 101(1):68-76. PubMed ID: 19132191
[TBL] [Abstract][Full Text] [Related]
10. Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.
Davis R; Faulds D
Drugs Aging; 1997 Apr; 10(4):299-322. PubMed ID: 9108990
[TBL] [Abstract][Full Text] [Related]
11. Low molecular weight heparin prevention of post-operative deep vein thrombosis in vascular surgery.
Speziale F; Verardi S; Taurino M; Nicolini G; Rizzo L; Fiorani P; Palazzini E
Pharmatherapeutica; 1988; 5(4):261-8. PubMed ID: 3174726
[TBL] [Abstract][Full Text] [Related]
12. [An effective method to prevent deep venous thrombosis in total hip arthroplasty: a study in patients with and without risk factors for thrombotic disease].
Pola E; Papaleo P; Cerciello S; Aulisa AG; Mazza O; Aulisa L
Clin Ter; 2003; 154(3):151-7. PubMed ID: 12910803
[TBL] [Abstract][Full Text] [Related]
13. Deep venous thrombosis after laparoscopic cholecystectomy and prevention with nadroparin.
Schaepkens Van Riempst JT; Van Hee RH; Weyler JJ
Surg Endosc; 2002 Jan; 16(1):184-7. PubMed ID: 11961636
[TBL] [Abstract][Full Text] [Related]
14. Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis.
Stricker H; Marchetti O; Haeberli A; Mombelli G
Thromb Haemost; 1999 Oct; 82(4):1227-31. PubMed ID: 10544903
[TBL] [Abstract][Full Text] [Related]
15. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.
Agnelli G; Gussoni G; Bianchini C; Verso M; Mandalà M; Cavanna L; Barni S; Labianca R; Buzzi F; Scambia G; Passalacqua R; Ricci S; Gasparini G; Lorusso V; Bonizzoni E; Tonato M;
Lancet Oncol; 2009 Oct; 10(10):943-9. PubMed ID: 19726226
[TBL] [Abstract][Full Text] [Related]
16. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of prothrombin fragment 1+2, thrombin antithrombin III complexes and D-dimer measurements in the diagnosis of deep vein thrombosis following total hip replacement.
Cofrancesco E; Cortellaro M; Corradi A; Ravasi F; Bertocchi F
Thromb Haemost; 1998 Mar; 79(3):509-10. PubMed ID: 9531030
[TBL] [Abstract][Full Text] [Related]
18. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group.
Charbonnier BA; Fiessinger JN; Banga JD; Wenzel E; d'Azemar P; Sagnard L
Thromb Haemost; 1998 May; 79(5):897-901. PubMed ID: 9609216
[TBL] [Abstract][Full Text] [Related]
19. Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study.
Jochberger S; Mayr V; Luckner G; Fries DR; Mayr AJ; Friesenecker BE; Lorenz I; Hasibeder WR; Ulmer H; Schobersberger W; Dünser MW
Crit Care; 2005 Oct; 9(5):R541-8. PubMed ID: 16277716
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of weight-adapted nadroparin calcium vs. heparin sodium in prevention of clinically evident thromboembolic complications in 1,190 general surgical patients.
Egger B; Schmid SW; Naef M; Wildi S; Büchler MW
Dig Surg; 2000; 17(6):602-609. PubMed ID: 11155006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
